Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer-Reference-Cited by-同舟云学术

Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer

Published:2018-09 Issue:5 Volume:19 Page:441-449.e4
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Bordoni Rodolfo,Ciardiello Fortunato,von Pawel Joachim,Cortinovis Diego,Karagiannis Thomas,Ballinger Marcus,Sandler Alan,Yu Wei,He Pei,Matheny Christina,Felizzi Federico,Rittmeyer Achim

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014

2. Oncology meets immunology: the cancer-immunity cycle;Chen;Immunity,2013

3. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1;Chen;Clin Cancer Res,2012

4. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial;Fehrenbacher;Lancet,2016

5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported outcomes and experiences from a prospective cohort study of older patients with cancer on checkpoint inhibitors: The ELDERS study;Journal of Geriatric Oncology;2024-06

2. A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology;Value in Health;2024-04

3. Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer;Heliyon;2024-02

4. Experience of patients considering or using checkpoint inhibitors in cancer treatment: a systematic review of qualitative research;Journal for ImmunoTherapy of Cancer;2024-01

5. Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies;Exploration of Targeted Anti-tumor Therapy;2023-10-10